BAYRYBAYRY
US • —
$13.70
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
-2.9% YoY
Gross Margin
59.3%
Health Score
4/10
D/E Ratio
1.44
Confidence
LOW
Business Snapshot
Bayer is a life science company with operations in pharmaceuticals, consumer health, and crop science. Its primary revenue-generating segments include prescription drugs, over-the-counter health products, and agricultural chemicals and seeds. The company operates in highly regulated global markets and holds leading positions in crop protection and non-prescription health products. Bayer is a large-cap entity, though its current market capitalisation and trailing twelve-month revenue figures are not available in this dataset. A defining characteristic is the significant debt burden stemming from its acquisition of Monsanto, which continues to weigh on its financial profile.
Financial Health
Gross margin stands at 59.3%, but no prior-year figure is available for comparison to assess trend direction. Net margin is deeply negative at -4.8%, indicating the company is not profitable on a trailing twelve-month basis and meaningfully lacks earnings power...
Risk Assessment
- EARNINGS QUALITY — Despite beating estimates in 4 of 4 recent quarters, the net margin of -4.8% and negative net income confirm underlying earnings are not sustainable.
- DEBT / LIQUIDITY — Debt/Equity of 1.44x combined with a current ratio of 1.01x indicates elevated leverage and minimal liquidity headroom.
- REVENUE DECELERATION — Revenue growth of -2.9% YoY confirms a contraction in the top line with no offsetting QoQ data available to show a near-term recovery.
- VALUATION — No P/E ratio is calculable due to negative earnings, and an EV/EBITDA of 29.88x is high for a company with negative net margins, suggesting premium pricing without profit support.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed....
Gross margin stands at 59.3%, but no prior-year figure is available for comparison to assess trend direction. Net margin is deeply negative at -4.8%, indicating the company is not profitable on a trailing twelve-month basis and meaningfully lacks earnings power. The balance sheet is stretched, with a Debt/Equity ratio of 1.44x signalling elevated leverage, while the current ratio of 1.01x suggests liquidity is tight and the company has minimal buffer to cover short-term obligations. Return on equity is -7.5%, confirming that the company is destroying shareholder value at the operating level. Free cash flow data is unavailable, so the company's ability to service its debt or fund reinvestment organically cannot be assessed from this dataset. Overall, financial health is weak and presents significant risk for equity holders, with limited margin for error.
- EARNINGS QUALITY — Despite beating estimates in 4 of 4 recent quarters, the net margin of -4.8% and negative net income confirm underlying earnings are not sustainable. - DEBT / LIQUIDITY — Debt/Equity of 1.44x combined with a current ratio of 1.01x indicates elevated leverage and minimal liquidity headroom. - REVENUE DECELERATION — Revenue growth of -2.9% YoY confirms a contraction in the top line with no offsetting QoQ data available to show a near-term recovery. - VALUATION — No P/E ratio is calculable due to negative earnings, and an EV/EBITDA of 29.88x is high for a company with negative net margins, suggesting premium pricing without profit support. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives